# A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)

> **NCT01431534** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 20 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Ridaforolimus

## Key facts

- **NCT ID:** NCT01431534
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01-30
- **Primary completion:** 2013-08-20
- **Final completion:** 2018-05-25
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01431534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01431534, "A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01431534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*